A recent report published by Infinium Global Research on the acute migraine drugs market provides in-depth analysis of segments and sub-segments in the global as well as regional acute migraine drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional acute migraine drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global acute migraine drugs market. According to the report, the global acute migraine drugs market is projected to reach USD 3 billion by 2027 from USD 2 billion in 2021, growing with a CAGR of 7%  over the forecast period of 2021-2027.

Market Insight

The global migraine drugs market exhibited strong growth during the forecast period. Migraine is known a neurological condition that causes unilateral or throbbing pain within the forehead, side of the pinnacle, or beside the eyes. The pain is usually because of autonomic symptoms, like nausea, vomiting, photophobia, and phonophobia. Migraine is usually diagnosed by examining the patient’s medical record and symptoms, further as by performing blood tests, resonance imaging, and computerized axial tomography scans. A major rise in the prevalence and diagnosis of migraine represents one of the key factors bolstering the market growth. Other than this, the development in reimbursement policies for migraine medications, together with the escalating demand for precision medicines, is additionally contributing to the market growth. Furthermore, the rising demand for electrical nerve stimulating devices to treat migraine and therefore the projected approval of recent classes of medication that are within the late-stage pipeline and have higher clinical efficacy, like the introduction of calcitonin gene-related peptide monoclonal antibodies, are boosting the market growth. The testing of migraine drugs for the treatment of coronavirus disease is anticipated to form a positive impact on the market growth.

The rising population worldwide, and therefore the growing demand for quality drugs are significant factors driving the expansion of the worldwide migraine drugs market. The prevalence of this disease is higher in women. Therefore, the growing female population worldwide could be a big plus to the worldwide migraine drugs market expansion. Additionally, factors like increasing work pressure, high alcohol consumption, growing demand for quality drugs, changes in lifestyles, and awareness among patients related to the prevention and treatment of migraine further increase the demand levels for the world migraine drugs market. Side effects that connect with migraine drugs are hampering the expansion of the market, additionally, stringent rules and regulations by the govt are hindering the expansion rate of the migraine drugs market. Also, drugs' harmful effects and therefore the increasing precedence of other therapies restrain the expansion during the forecast period.

Among the regions, North America holds the biggest market share of the Acute Migraine Drugs Market. The increasing number of patients, growing investments in R&D activities, and the establishment of technically advanced research centers will contribute to the Acute Migraine Drugs Market growth in the region. However, the Asia Pacific is expected to perform the fastest growth of the Acute Migraine Drugs Market. The rise in focus of vendors on the emerging markets, such as Asia-Pacific and LAMEA, is expected to boost the market growth. Asia-Pacific is anticipated to observe major growth in the forecast period, due to increasing demand for better healthcare facilities and rising healthcare infrastructure. Furthermore, this region presents remarkable opportunities for venture capitalists and investors, as the developed markets are comparatively saturated.

Segment Covered

The report on the global acute migraine drugs market covers segments such as drug, application, and distribution channel. On the basis of drug, the sub-markets include abortive medicine, and preventive medicine. On the basis of application, the sub-markets include oral, injectable, and nasal sprays. On the basis of distribution channel, the sub-markets include hospital-based pharmacies, retail pharmacies, and online pharmacies.

Companies Profiled:

The report provides profiles of the companies in the market such as Endo Pharmaceuticals Inc, Allergan, Impax Laboratories, Glaxo Smith Kline, Astellas, Amgen, Bayer, AstraZeneca, Dr. Reddy’s Laboratories, and Zogenix.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the acute migraine drugs market. Moreover, the study highlights current market trends and provides forecast from 2021-2027. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.